{"id":46060,"date":"2022-07-12T12:03:04","date_gmt":"2022-07-12T10:03:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/"},"modified":"2022-07-12T12:03:04","modified_gmt":"2022-07-12T10:03:04","slug":"greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/","title":{"rendered":"Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed"},"content":{"rendered":"
\n

STAFFORD, Texas–(BUSINESS WIRE)–Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that the Food and Drug Administration (FDA) has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed.\n<\/p>\n

<\/a><\/p>\n

\nAs previously announced, the Phase III clinical trial was placed on clinical hold by the FDA related to manufacturing and the pharmacy process. The Company through discussions with the FDA and testing of GP2 in the pharmacy process has satisfactorily addressed the clinical hold issues. The Company has committed to additional testing of GP2 in the pharmacy process. On July 11, 2022, the FDA formally removed the clinical hold and thus the Flamingo-01 Phase III clinical trial may proceed as planned. The Company has begun site initiation visits and will provide further updates on the progress of Flamingo-01 in the future.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCompany Contact<\/b>
Snehal Patel
\n
Investor Relations
\n
Office: (832) 819-3232
\n
Email: info@greenwichlifesciences.com<\/a>\n<\/p>\n

\nInvestor & Public Relations Contact for Greenwich LifeSciences<\/b>
Dave Gentry
\n
RedChip Companies Inc.
\n
Office: 1-800-RED CHIP (733 2447)
\n
Cell: (407) 491-4498
\n
Email: dave@redchip.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

STAFFORD, Texas–(BUSINESS WIRE)–Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that the Food and Drug Administration (FDA) has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed. As previously announced, the Phase III clinical trial was placed on clinical hold by … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-46060","format-standard","category-industry"],"yoast_head":"\nGreenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"STAFFORD, Texas–(BUSINESS WIRE)–Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that the Food and Drug Administration (FDA) has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed. As previously announced, the Phase III clinical trial was placed on clinical hold by ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-12T10:03:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220712005542\/en\/828614\/21\/GLSI-logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed\",\"datePublished\":\"2022-07-12T10:03:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\\\/\"},\"wordCount\":192,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220712005542\\\/en\\\/828614\\\/21\\\/GLSI-logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\\\/\",\"name\":\"Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220712005542\\\/en\\\/828614\\\/21\\\/GLSI-logo.jpg\",\"datePublished\":\"2022-07-12T10:03:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220712005542\\\/en\\\/828614\\\/21\\\/GLSI-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220712005542\\\/en\\\/828614\\\/21\\\/GLSI-logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/","og_locale":"en_US","og_type":"article","og_title":"Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed - Pharma Trend","og_description":"STAFFORD, Texas–(BUSINESS WIRE)–Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that the Food and Drug Administration (FDA) has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed. As previously announced, the Phase III clinical trial was placed on clinical hold by ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-12T10:03:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220712005542\/en\/828614\/21\/GLSI-logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed","datePublished":"2022-07-12T10:03:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/"},"wordCount":192,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220712005542\/en\/828614\/21\/GLSI-logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/","url":"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/","name":"Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220712005542\/en\/828614\/21\/GLSI-logo.jpg","datePublished":"2022-07-12T10:03:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220712005542\/en\/828614\/21\/GLSI-logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220712005542\/en\/828614\/21\/GLSI-logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/greenwich-lifesciences-announces-removal-of-clinical-hold-permitting-phase-iii-clinical-trial-to-proceed\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46060"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46060\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}